Focusing on cell therapy applications, Formosa Biomedical Technology (FBC) acquired more than half of the shares of Ivy Life Sciences to join hands in developing cancer cell therapy; the core technology platform of CIK autoimmune killer cell medical technology (IKC for short) has been patented in three countries and completed phase II human clinical trials for terminal non-small cell lung cancer.

Bionet Therapeutics has had 14 cell therapy projects approved, accounting for 80% of the total number of approved projects in Taiwan, including the first company in Taiwan to approve autologous fat stem cell therapy for chronic injuries. In addition, the company has established a new joint venture with its subsidiary, Genetics Generation Advancement, to accelerate the development of new cell therapy drugs and strengthen its long-term business base.

In addition, cutting-edge cell technology has helped Taiwan Advance Bio-Pharmaceutical drive revenue to a record high for the sixth consecutive month last year, with an annual growth rate of 34.61%. The company is looking forward to its cell-based CDMO orders and cell therapy projects, offering more than 10 indications, including immune cell therapy for lung, oesophageal and gastric cancers, and mesenchymal stem cell products for degenerative arthritis, cartilage defects in the knee and spinal cord injury.

Formosa Biomedical pointed out that Ivy Life Sciences is already a national leader in the field of liver and lung cancer cell therapy, and will upgrade the GTP laboratory specifications to GMP level as soon as possible. This year, we will add nine more hospitals to the existing nine and expand the number of indications to seven more.

At present, Bionet is in partnership with five clinics with a focus on wound treatment. The new company, which was co-founded with Genetics Generation Advancement, is already developing applications in exosomes, new cellular drugs, regenerative therapeutics, gene and cell therapy, and will accelerate the commercialisation of its technologies in the future.

At present, the hospitals with which Taiwan Advance Bio-Pharmaceutical is working include Hualien Tzu-Chi Hospital, Kuang Tien General Hospital, Shin Kong Hospital, Taipei Medical University Hospital and Taichung Tzu-Chi Hospital, etc. the company is expanding its business performance by focusing on both "treatment" and "preservation" strategies.